Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Ibrutinib
Related studies linked through entity extraction aliases.
A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice
- Status
- COMPLETED
- Phase
- N/A
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
- Status
- COMPLETED
- Phase
- PHASE1
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib
- Status
- TERMINATED
- Phase
- PHASE1
Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy
- Status
- COMPLETED
- Phase
- PHASE1
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
- Status
- TERMINATED
- Phase
- PHASE1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE2